Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

Completed · Phase 2

Conditions studied: Breast Neoplasms

In brief

The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.

Key facts

Study ID: NCT02756364
Run by: Calithera Biosciences, Inc
People needed: 141
Starts: 2016-07-28
Expected to finish: 2019-11-25
Last updated by the study team: 2023-02-08

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Female participants aged 18 years or older who are postmenopausal.
Histologically proven diagnosis of breast cancer with evidence of metastatic disease or locoregional recurrence.
Histological confirmation and documentation of estrogen receptor (ER)-positive status (≥1% positive stained cells).
Histological or cytological confirmation and documentation of human epidermal growth factor receptor-2 (HER2)-negative status by local laboratory testing using criteria in the American Society of Oncology (ASCO)/College of American Pathologists (CAP) Clinical Practice Guideline update.
Measurable disease defined as either of the following:
At least 1 extra-osseous lesion that could be accurately measured in at least 1 dimension.
The lesion must have measured ≥20 mm with conventional imaging techniques or ≥10 mm with spiral CT or MRI. Lymph nodes must be ≥1.5 cm in the short axis to be considered measurable.
Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable disease as defined above. Note: Participants with sclerotic/osteoblastic bone lesions only, in the absence of measurable disease, were not eligible.
Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.
Have a history of brain metastasis provided that all of the following criteria are met:
Brain metastases have been treated.
No evidence of PD for ≥3 months before the first dose of study drug.
No hemorrhage after treatment.
Off dexamethasone treatment for ≥4 weeks before the first dose of study drug.
No ongoing requirement for dexamethasone or anti-epileptic drugs.
Eastern cooperative oncology group (ECOG) performance status of 0 or 1.
Clinical laboratory values as specified below within 4 weeks before the first dose of study drug:
Bone marrow reserve consistent with absolute neutrophil count (ANC) ≥1.5*10\^9/L; platelet count ≥100*10\^9/L; hemoglobin (Hgb) ≥9 g/dL.
Total bilirubin ≤1.5*the upper limit of the normal range (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5*ULN (≤5*ULN if liver metastases are present).
Creatinine clearance ≥40 mL/min based on Cockcroft-Gault estimate or based on a 12- or 24-hour urine collection.
Fasting serum glucose ≤130 mg/dL and fasting triglycerides ≤300 mg/dL.

You may not qualify if…

Prior therapy with mechanistic target of rapamycin (mTOR), phosphoinositide-3-kinase (PI3K), or dual PI3K-mTOR inhibitors, serine/threonine-specific protein kinase (AKT) inhibitors, or fulvestrant.
Prior treatment with >1 line of chemotherapy for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Experienced PD on >2 endocrine therapies for metastatic breast cancer or for locoregional recurrence that was not amenable to resection or radiation therapy with curative intent.
Life-threatening metastatic visceral disease (defined as extensive hepatic involvement or symptomatic pulmonary lymphangitic spread).
Poorly controlled diabetes mellitus defined as hemoglobin A1c (glycosylated hemoglobin; HbA1c) >7%; participants with a history of transient glucose intolerance due to corticosteroid administration may be eligible if all other inclusion/exclusion criteria are met.

Where it is running

CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA — Bakersfield, California, United States
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare — Fullerton, California, United States
UCSD Moores Cancer Center — La Jolla, California, United States
UCLA Hematology/Oncology David Geffen School of Medicine — Los Angeles, California, United States
North County Oncology — Oceanside, California, United States
Torrance Health Association — Redondo Beach, California, United States
PHC-SLO Oncology and Hematology — San Luis Obispo, California, United States
Cancer Center of Santa Barbara With Sansum Clinic — Santa Barbara, California, United States
University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP) — Aurora, Colorado, United States
St. Mary'S Hospital Regional Cancer Center — Grand Junction, Colorado, United States
Rocky mountain cancer centers LLP — Lakewood, Colorado, United States
Holy Cross Hospital- Bienes Cancer Center — Fort Lauderdale, Florida, United States
Memorial Healthcare System — Hollywood, Florida, United States
Orlando Health Inc. — Orlando, Florida, United States
Ft. Wayne Medical Oncology and Hematology, Inc — Fort Wayne, Indiana, United States
New England Cancer Specialists — Scarborough, Maine, United States
Health Partners Institute Park Nicollet Frauenshuh Cancer Center — Saint Louis Park, Minnesota, United States
Comprehensive Cancer Centers of Nevada — Henderson, Nevada, United States
New Jersey Hematology & Oncology Associates — Brick, New Jersey, United States
Northern Westchester Hospital Cancer Treatment & Wellness Center — Mount Kisco, New York, United States
Oregon Health and Science University — Portland, Oregon, United States
Texas Oncology, P.A. — Austin, Texas, United States
Texas Oncology - Presbyterian Hospital — Dallas, Texas, United States
Texas Oncology, P.A. — Dallas, Texas, United States
Southern Cancer Center, PC — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.